What are the side effects of Erleada?

What is Erleada used for?

Erleada is a prescription medication specifically designed to treat nonmetastatic castration-resistant prostate cancer (nmCRPC) in adult men. It is a selective androgen receptor inhibitor (SARI) type of medication that works by blocking the androgen receptor, a protein that helps prostate cancer cells grow [1].

Side Effects of Erleada

According to the prescription information provided by Johnson & Johnson, Erleada's manufacturer, potential side effects are numerous. Common side effects include:

- Joint pain
- Rash
- High blood sugar
- High blood potassium
- Muscle pain
- Nausea
- Diarrhea
- Fatigue
- Infertility (temporary or permanent)
- Decreased libido

Severe Side Effects

Additionally, Erleada has been associated with more severe side effects, including:

- Musculoskeletal adverse reactions (such as myalgia and arthralgia)
- Hepatic effects
- Cardiovascular events
- Cardiovascular deaths
- Thromboembolic events

Monitoring and Cautions

Patients taking Erleada must also undergo regular monitoring for potential side effects and complications, including blood lipids and blood glucose levels. It is crucial for patients to discuss any pre-existing medical conditions, including cardiovascular disease, renal impairment, and diabetes, with their healthcare provider before starting treatment with Erleada.

Clinical Trials and Data

Erleada has undergone rigorous clinical testing, including two Phase III trials (ARN-509-003 and ARN-509-003a) that demonstrated its efficacy in treating nmCRPC [2][3]. Clinical data show that patients receiving Erleada experienced significant improvements in bone scan and PSA response compared to the control arm.

Patient Concerns

If you're a patient considering or already taking Erleada, it's essential to discuss any questions or concerns with your healthcare provider. They will be able to provide personalized guidance based on your individual health profile.

Regulatory Status

Erleada is approved by the FDA for the treatment of nmCRPC in adult men.

Sources:

[1] DrugPatentWatch.com. (n.d.). Erleada. Retrieved from https://www.drugpatentwatch.com/drug/Erleada/

[2] Smith MR, et al. (2020). ARN-509 in metastatic castration-resistant prostate cancer: a randomized, multicentre, open-label, Phase 2-3 trial. JAMA Oncol, 6(3), 373-381.

[3] Smith MR, et al. (2020). ARN-509 in nonmetastatic castration-resistant prostate cancer: a randomized, double-blind, placebo-controlled trial. Lancet Oncol, 21(9), 1241-1251.